Alkermes ALKS · NASDAQ
$45.90 +3.05% (+$1.36)
Summary
35 / 100 · Bulios Score
What speaks for it
- Analysts expect revenue to grow by 24% this fiscal year.
- Out of every 100 USD of revenue, 13 USD is left as free cash.
What to watch
- The company made a loss over the last 12 months.
- Repaying its net debt would take 5.3 years of operating profit.
- The share price is above the Bulios Fair Price.
- It passes only 2 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 7.3% a year over 5 years. Over the last 3 years it grew by 9.9% a year. For the next fiscal year analysts expect revenue to grow by 24%.
Growth in detailDoes it make money?
ReasonablyOver the last 12 months it made a loss of $351.0K.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 6.9 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 16
- Hold 10
- Sell 3
Today's price within the analysts' price targets
The average target of $58.29 is 27% above today's price. 55% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Vivitrol 40%
- Aristada And Aristada Initio 31%
- Manufactured Product And Royalty 25%
- Manufacturing Revenue 3.9%
By region
- UNITED STATES 93%
- Foreign Country Excluding Specified Country 6.9%
- IRELAND 0.1%
Vivitrol brings in 40% of revenue.
Segments in detail